Oral tranexamic acid treats papulopustular rosacea by improving the skin barrier
Journal of Cosmetic Dermatology · 2024
DOI: 10.1111/jocd.16339 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2024. Verfasst von Zining Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: Rosacea, Tranexamic Acid, Quality of Life. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Xi'an Jiaotong University Free Exploration Project.
Abstract (Originalsprache)
Background
Papulopustular rosacea (PPR) is a chronic inflammatory disease with a significant impact on facial aesthetics. An impaired skin barrier is an important factor in the development and exacerbation of PPR. Tranexamic acid (TXA) has immune regulatory and anti‐inflammatory effects, inhibits angiogenesis and endothelial hyperplasia, and promotes skin barrier repair.
Aims
We investigated the efficacy and safety of oral TXA for PPR treatment. Patients/Methods In total, 70 patients were randomly assigned to receive traditional therapy plus oral TXA or traditional therapy alone for 8 weeks, with a 4‐week follow‐up period. The subjective improvement in rosacea was assessed using the clinical erythema assessment (CEA), investigator's global assessment (IGA), patient self‐assessment (PSA) score, rosacea‐specific quality of life (RQoL) score, and global aesthetic improvement score (GAIS). An objective improvement in rosacea was assessed using skin hydration, trans‐epidermal water loss (TEWL), clinical photography, and an eight spectrum facial imager.
Results
CEA/IGA/PSA, dryness, and RQoL scores were significantly lower and GAIS was higher in the TXA group than in the traditional therapy group. Furthermore, oral TXA significantly improved skin barrier function, increased skin hydration, and decreased TEWL, with no significant side effects. Notably, we observed better outcomes and a greater improvement in skin barrier function with TXA treatment in patients with dry‐type rosacea than in patients with oily skin.
Conclusions
The addition of oral TXA to traditional therapy can lead to rapid and effective improvements in PPR, which may be attributed to improvements in skin barrier function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- Department of Dermatology, Taihe Hospital, Hubei University of Medicine, Shi'yan, China.
- Department of Dermatology, Xi'an International Medical Center Hospital, Xi'an, China.
- Department of Neurology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- Department of Nursing, The Medicine of Xi'an Jiaotong University, Xi'an, China.
Förderung
- Xi'an Jiaotong University Free Exploration Project
Zitieren
APA
Xu, Z., Yu, B., Xu, B., Ye, S., Qing, Y., Zhao, B., Hong, S., Wu, N., & Wu, J. (2024). Oral tranexamic acid treats papulopustular rosacea by improving the skin barrier. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16339
Vancouver
Xu Z, Yu B, Xu B, Ye S, Qing Y, Zhao B, et al. Oral tranexamic acid treats papulopustular rosacea by improving the skin barrier. Journal of Cosmetic Dermatology. 2024. doi:10.1111/jocd.16339
BibTeX
@article{Xu2024,
author = {Xu, Zining and Yu, Biao and Xu, Bingyang and Ye, Shuhong and Qing, Yuxin and Zhao, Bin and Hong, Sun and Wu, Na and Wu, Jiawen},
title = {Oral tranexamic acid treats papulopustular rosacea by improving the skin barrier},
journal = {Journal of Cosmetic Dermatology},
year = {2024},
doi = {10.1111/jocd.16339}
}
EUVIMED